4L1E image
Entry Detail
PDB ID:
4L1E
Keywords:
Title:
Crystal structure of C-Phycocyanin from Leptolyngbya sp. N62DM
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2013-06-03
Release Date:
2014-05-21
Method Details:
Experimental Method:
Resolution:
2.61 Å
R-Value Free:
0.28
R-Value Work:
0.23
R-Value Observed:
0.24
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Phycocyanin alpha chain
Chain IDs:A, C, E, G, I, K
Chain Length:162
Number of Molecules:6
Biological Source:Leptolyngbya sp. N62DM
Polymer Type:polypeptide(L)
Description:Phycocyanin beta chain
Chain IDs:B, D, F, H, J, L
Chain Length:172
Number of Molecules:6
Biological Source:Leptolyngbya sp. N62DM
Primary Citation
Crystal Structure and Interaction of Phycocyanin with beta-Secretase: A Putative Therapy for Alzheimer's Disease.
CNS Neurol Disord Drug Targets 13 691 698 (2014)
PMID: 24576002

Abstact

Alzheimer's disease (AD) represents a neurological disorder, which is caused by enzymatic degradation of an amyloid precursor protein into short peptide fragments that undergo association to form insoluble plaques. Preliminary studies suggest that cyanobacterial extracts, especially the light-harvesting protein phycocyanin, may provide a means to control the progression of the disease. However, the molecular mechanism of disease control remains elusive. In the present study, intact hexameric phycocyanin was isolated and crystallized from the cyanobacterium Leptolyngbya sp. N62DM, and the structure was solved to a resolution of 2.6 A. Molecular docking studies show that the phycocyanin αβ-dimer interacts with the enzyme β-secretase, which catalyzes the proteolysis of the amyloid precursor protein to form plaques. The molecular docking studies suggest that the interaction between phycocyanin and β-secretase is energetically more favorable than previously reported inhibitor-β-secretase interactions. Transgenic Caenorhabditis elegans worms, with a genotype to serve as an AD-model, were significantly protected by phycocyanin. Therefore, the present study provides a novel structure-based molecular mechanism of phycocyanin-mediated therapy against AD.

Legend

Protein

Chemical

Disease

Primary Citation of related structures